David, Joseph and Kathyrn, with respect to the RESULT: For respondents.
death by suicide of their father, Mark S., 50. Decedent suffered depression when his wife, EXPERT TESTIMONY: Mace Beckson,
Shanna S. left him, and as a result of his minor M.D., testified that it was below the standard daughter’s developmental disabilities, alleged of care to prescribe Effexor to a patient with
to be the result of the respondent’s negligence a prior suicide attempt, and that the Effexor (and the subject of another action).
increased the patient’s risk of suicidality.
CASE: Sasha S., a minor by and through her
Alleged that the monitoring of the patient by
Guardian ad Litem Shanna S.; David S.; Joseph Decedent began psychiatric treatment for his psychiatrist and therapist, both employees
S.; Kathryn S. v. Kaiser Foundation Health depression with the respondents on March of the respondent, was negligent and that
Plans Inc.; Kaiser Foundation Hospitals; 3, 2006 and continued off and on until he they were not aware of or did not appreciate
Southern California Permanente Medical committed suicide on Dec. 19, 2007.
the significance of the patient’s prior suicide
attempt. Alleged that the patient should
CLAIMANT’S CONTENTIONS: Claimants have been hospitalized when he requested
contended that decedent was not properly hospitalization for ECT (electroconvulsive
monitored and followed by his mental health therapy) and that instead, when the patient
ATTORNEYS: Claimant — Tera A. Harden professionals, particularly after a suicide presented to the hospital, he was turned away.
(Law Offices of Brian C. Pearcy, Riverside) attempt; was turned away from Kaiser for As a result, he felt he had no options and
for David S., Joseph S., Kathryn S.; Patricia a psychiatric admission for ECT therapy committed suicide.
A. Law (Law Offices of Patricia A. Law, during the week prior to his suicide; and was Riverside) for Sasha S.
prescribed Effexor that increased his suicidal Lester Zackler, M.D., testified that Effexor ideation, all of which caused or contributed to was an appropriate treatment choice, and it
Respondent — N. Denise Taylor (Taylor
his death by suicide.
does not cause suicidal ideation. Further, the
Blessey, LLP, Los Angeles
decedent was offered psychiatry appointments
R E S P O N D E N T ’ S C O N T E N T I O N S : and counseling sessions but chose not to
MEDICAL EXPERTS: Claimant — Mace Respondents contended that all of the care attend on a regular basis. The patient was
Beckson, M.D., forensic psychiatry/addiction and treatment provided to decedent by the non-compliant in his treatment, and denied
respondents’ agents and employees, including suicidal ideation. The patient was referred
Respondent — Lester Zackler, M.D., his psychiatrists and therapists was within the for ECT evaluation when he requested it, but neuropsychiatry, Sherman Oaks.
standard of care and did not cause or contribute failed to go to the hospital on the appointed to the suicide of decedent.
date, and failed to follow-up with his mental
health care professionals thereafter, instead
brought by minor claimant Sasha S., by and SETTLEMENT DISCUSSIONS: Claimants deciding to end his life by suicide. through her mother and Guardian ad Litem, demanded $500,000. Respondents made no Shanna S. and decedent’s three adult children offer.
Reprinted with permission from the Daily Journal.
2011, Daily Journal Corporation. All rights reserved.
Reprinted by Scoop ReprintSource 1-800-767-3263
PROGRAM FOR KONFERENCEN FM I STRATEGISK LEDELSEVelkomst og indledning Birgitte Dyrvig Carlsson, afdelingsleder, Cowi A/S, ordstyrer, bestyrelsesmedlem, DFM-netværk Facilities Management en strategisk ledelsesdisciplinHovedelementerne i Facilities Management og beskrivelse af, hvordan Facilities Management har Ændring fra udbygningsfokuseret FM til FM som integreret del af museets strategiske
Riassunto delle caratteristiche del prodotto eventi avversi di fratture ossee riportati da studi clinici randomizzati, controllati, in doppio ciecoin oltre 8.100 pazienti trattati con pioglitazone e 7.400 trattati con farmaco di confronto per unperiodo superiore ai 3,5 anni, è stata osservata un’aumentata incidenza di fratture ossee nelledonne. Sono state osservate fratture nel 2,6% delle